$AMRN
AMARIN CORP PLC\UK Stock $amrn

$amrn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000095017024022636 Filed on February 29, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$74.71M	$306.9M
YoY Change	-17.21%	-16.87%
Cost Of Revenue	$29.59M	$102.1M
YoY Change	11.07%	-5.97%
Gross Profit	$45.12M	$165.5M
YoY Change	-29.05%	-31.73%
Gross Profit Margin	60.4%	53.94%
Selling, General & Admin	$43.94M	$199.9M
YoY Change	-35.51%	-34.32%
% of Gross Profit	97.38%	120.78%
Research & Development	$5.791M	$22.22M
YoY Change	10.54%	-26.94%
% of Gross Profit	12.83%	13.42%
Depreciation & Amortization	$735.0K	$200.0K
YoY Change	-3.42%	-66.67%
% of Gross Profit	1.63%	0.12%
Operating Expenses	$49.73M	$233.1M
YoY Change	-32.22%	-33.08%
Operating Profit	-$4.608M	-$67.59M
YoY Change	-52.82%	-36.16%
Interest Expense	$3.417M	$8.000K
YoY Change	118.62%	-46.67%
% of Operating Profit
Other Income/Expense, Net	-$1.029M	$2.063M
YoY Change	-182.32%	-378.78%
Pretax Income	-$2.449M	-$53.67M
YoY Change	-63.84%	-48.3%
Income Tax	$3.332M	$5.442M
% Of Pretax Income
Net Earnings	-$5.781M	-$59.11M
YoY Change	-775.35%	-44.13%
Net Earnings / Revenue	-7.74%	-19.26%
Basic Earnings Per Share		-$0.15
Diluted Earnings Per Share	-$0.01	-$0.15
COMMON SHARES
Basic Shares Outstanding		407.7M
Diluted Shares Outstanding		407.7M

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$320.7M	$320.7M
YoY Change	3.65%	3.65%
Cash & Equivalents	$199.3M	$199.3M
Short-Term Investments	$121.4M	$121.4M
Other Short-Term Assets	$12.14M	$12.14M
YoY Change	-39.33%	-39.33%
Inventory	$258.6M	$258.6M
Prepaid Expenses
Receivables	$133.6M	$133.6M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$725.0M	$725.0M
YoY Change	5.21%	5.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$114.0K	$8.424M
YoY Change	-86.96%	-15.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Assets	$1.360M	$78.98M
YoY Change	196.94%	-51.87%
Total Long-Term Assets	$106.7M	$106.7M
YoY Change	-45.87%	-45.86%
TOTAL ASSETS
Total Short-Term Assets	$725.0M	$725.0M
Total Long-Term Assets	$106.7M	$106.7M
Total Assets	$831.7M	$831.7M
YoY Change	-6.15%	-6.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$52.76M	$52.76M
YoY Change	-18.33%	-18.33%
Accrued Expenses	$204.2M	$178.6M
YoY Change	5.97%	13.72%
Deferred Revenue	$2.341M
YoY Change	6.46%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$259.3M	$259.3M
YoY Change	-0.08%	-0.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.064M	$20.31M
YoY Change	10.47%	-35.25%
Total Long-Term Liabilities	$9.064M	$20.31M
YoY Change	10.47%	-35.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$259.3M	$259.3M
Total Long-Term Liabilities	$9.064M	$20.31M
Total Liabilities	$279.6M	$279.6M
YoY Change	-3.87%	-3.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.586B
YoY Change	3.87%
Common Stock	$302.8M
YoY Change	1.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$63.75M
YoY Change	3.21%
Treasury Stock Shares
Shareholders Equity	$552.1M	$552.1M
YoY Change
Total Liabilities & Shareholders Equity	$831.7M	$831.7M
YoY Change	-6.15%	-6.15%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$5.781M	-$59.11M
YoY Change	-775.35%	-44.13%
Depreciation, Depletion And Amortization	$735.0K	$200.0K
YoY Change	-3.42%	-66.67%
Cash From Operating Activities	-$650.0K	$6.880M
YoY Change	-141.88%	-103.82%
INVESTING ACTIVITIES
Capital Expenditures	$513.0K	$533.0K
YoY Change	-14.36%	-11.02%
Acquisitions
YoY Change
Other Investing Activities	-$70.49M	-$24.99M
YoY Change	158.96%	-114.21%
Cash From Investing Activities	-$71.00M	-$25.52M
YoY Change	155.23%	-114.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	230.0K
YoY Change	110.53%	-160.69%
NET CHANGE
Cash From Operating Activities	-650.0K	6.880M
Cash From Investing Activities	-71.00M	-25.52M
Cash From Financing Activities	80.00K	230.0K
Net Change In Cash	-71.57M	-18.41M
YoY Change	172.87%	255.24%
FREE CASH FLOW
Cash From Operating Activities	-$650.0K	$6.880M
Capital Expenditures	$513.0K	$533.0K
Free Cash Flow	-$1.163M	$6.347M
YoY Change	-222.04%	-103.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000897448
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Registrant Name EntityRegistrantName	AMARIN CORP PLC\UK
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.amarincorp.com/20231231#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2023	us-gaap	Operating Lease Income Comprehensive Income Extensible List OperatingLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-21392
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Iconic Offices, The Greenway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Block C Ardilaun Court
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	112-114 St Stephens Green
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2
CY2023	dei	Entity Address Country EntityAddressCountry	IE
CY2023	dei	City Area Code CityAreaCode	353 (0) 1
CY2023	dei	Local Phone Number LocalPhoneNumber	6699 020
CY2023	dei	Security12b Title Security12bTitle	American Depositary Shares (ADS(s)), each ADSrepresenting the right to receive one (1) Ordinary Share ofAmarin Corporation plc
CY2023	dei	Trading Symbol TradingSymbol	AMRN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	484700000
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	199252000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	217666000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	525000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	523000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	121407000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	91695000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	133563000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130990000
CY2023Q4	us-gaap	Inventory Net InventoryNet	258616000
CY2022Q4	us-gaap	Inventory Net InventoryNet	228732000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11618000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19492000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	724981000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	689098000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	874000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1275000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	77615000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	163620000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8310000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9074000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1360000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	458000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19304000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21780000
CY2023Q4	us-gaap	Assets Assets	831684000
CY2022Q4	us-gaap	Assets Assets	886179000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	52762000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	64602000
CY2023Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	204174000
CY2022Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	192678000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2341000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2199000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	259277000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	259479000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2509000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13147000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8737000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10015000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9064000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8205000
CY2023Q4	us-gaap	Liabilities Liabilities	279587000
CY2022Q4	us-gaap	Liabilities Liabilities	290846000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	418141295
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	408824093
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	412333087
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	404346256
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	302756000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	299002000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1899456000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1885352000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	9317202
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7986831
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	63752000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	61770000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1586363000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1527251000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	552097000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	595333000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	831684000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	886179000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	306911000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	369193000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	583187000
CY2023	us-gaap	Cost Direct Material CostDirectMaterial	102142000
CY2022	us-gaap	Cost Direct Material CostDirectMaterial	108631000
CY2021	us-gaap	Cost Direct Material CostDirectMaterial	121327000
CY2023	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	39228000
CY2022	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	18078000
CY2023	us-gaap	Gross Profit GrossProfit	165541000
CY2022	us-gaap	Gross Profit GrossProfit	242484000
CY2021	us-gaap	Gross Profit GrossProfit	461860000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	199938000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	304416000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	408334000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22219000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30411000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29307000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	10972000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	13526000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	13717000
CY2023	us-gaap	Operating Expenses OperatingExpenses	233129000
CY2022	us-gaap	Operating Expenses OperatingExpenses	348353000
CY2021	us-gaap	Operating Expenses OperatingExpenses	451358000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-67588000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-105869000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	10502000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	11863000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2819000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1220000
CY2023	us-gaap	Interest Expense InterestExpense	8000
CY2022	us-gaap	Interest Expense InterestExpense	15000
CY2021	us-gaap	Interest Expense InterestExpense	129000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2063000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-740000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-302000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53670000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103805000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11291000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5442000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1998000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59112000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105803000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7729000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	407655000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	401155000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	395992000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	407655000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	401155000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	402480000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	667099000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	605000
CY2022	amrn	Stock Issued During Period Value Milestone Payment StockIssuedDuringPeriodValueMilestonePayment	8203000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	60000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1044000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26213000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105803000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	595333000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	330000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1882000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1982000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15646000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59112000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	552097000
CY2023	us-gaap	Profit Loss ProfitLoss	-59112000
CY2022	us-gaap	Profit Loss ProfitLoss	-105803000
CY2021	us-gaap	Profit Loss ProfitLoss	7729000
CY2023	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	160000
CY2022	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	551000
CY2021	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	587000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3696000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-473000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1929000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	15646000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26213000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36938000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2805000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2545000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2270000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2573000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-32663000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9079000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-56121000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	36422000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	167066000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7874000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2860000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8595000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	278000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24000
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-248000
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-341000
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-738000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10496000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1363000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1923000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-164000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-102729000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	51516000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	345000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	581000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1253000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6880000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-180092000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66537000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	190108000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	257520000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	394294000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	215097000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	81633000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	290195000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	509000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	599000
CY2023	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	-24000
CY2021	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	4000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25522000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	175288000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	104103000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	330000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	605000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1650000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1882000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2921000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1982000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1044000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9644000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	230000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-379000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5073000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18412000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5183000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32493000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	218189000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223372000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	190879000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	199777000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	218189000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223372000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2367000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1782000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3656000
CY2021	amrn	Non Cash Or Part Non Cash Milestone Payment NonCashOrPartNonCashMilestonePayment	12000000
CY2022	amrn	Shares Issued In Settlement Of Milestone Payment SharesIssuedInSettlementOfMilestonePayment	8203000
CY2023	amrn	Initial Recognition Of Operating Lease Right Of Use Asset InitialRecognitionOfOperatingLeaseRightOfUseAsset	607000
CY2022	amrn	Initial Recognition Of Operating Lease Right Of Use Asset InitialRecognitionOfOperatingLeaseRightOfUseAsset	2041000
CY2023	amrn	Initial Recognition Of Furniture Fixtures And Equipment Lease InitialRecognitionOfFurnitureFixturesAndEquipmentLease	624000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Assets Assets	831700000
CY2023Q4	amrn	Cash And Short Term Investments CashAndShortTermInvestments	320700000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	725000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	199300000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	121400000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	133600000
CY2023Q4	us-gaap	Inventory Net InventoryNet	258600000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	77600000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:2.253%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Estimates and assumptions relied upon in preparing these consolidated financial statements relate to, but are not limited to, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such items as provisions for sales returns, rebates and incentives, chargebacks, and other sales allowances; depreciable/amortizable lives; asset impairments; valuation allowance on deferred taxes; probabilities of achievement of performance conditions for certain equity awards; amounts recorded for licensing revenue; contingencies and accruals. Because of the uncertainties inherent in such estimates, actual results may differ from these estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	amrn	Accounts Receivable Credit Period AccountsReceivableCreditPeriod	P45D
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	160686000
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	187418000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	133563000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130990000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59112000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-59112000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105803000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-105803000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7729000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7729000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	407655000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	401155000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	395992000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	407655000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	401155000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	402480000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:2.253%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, short-term and long-term investments, and accounts receivable. The Company maintains substantially all of its cash and cash equivalents and short-term and long-term investments, in financial institutions believed to be of high-credit quality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A significant portion of the Company’s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or any other security to support credit sales. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for 10% or more of the Company’s gross product sales. Customers A, B, and C accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of gross product sales for the year ended December 31, 2023 and represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of the gross accounts receivable balance as of December 31, 2023. Customers A, B, and C accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of gross product sales for the year ended December 31, 2022 and represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of the gross accounts receivable balance as of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has not experienced any significant write-offs of its accounts receivable. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected.</span></p>
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-2600000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-700000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-600000
CY2023	us-gaap	Debt Instrument Term DebtInstrumentTerm	P24M
CY2022Q4	amrn	Held To Maturity Securities Continuous Unrealized Gain Loss Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedGainLossPositionFairValue	400000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	39200000
CY2022	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	18100000
CY2021Q3	amrn	Number Of Sales Representatives NumberOfSalesRepresentatives	300
CY2022Q2	amrn	Number Of Sales Representatives NumberOfSalesRepresentatives	75
CY2021Q3	amrn	Number Of Sales Representatives NumberOfSalesRepresentatives	300
CY2023	amrn	Employee Restructuring Separation Charges EmployeeRestructuringSeparationCharges	10383000
CY2022	amrn	Employee Restructuring Separation Charges EmployeeRestructuringSeparationCharges	9310000
CY2021	amrn	Employee Restructuring Separation Charges EmployeeRestructuringSeparationCharges	13717000
CY2023	amrn	Vendor Contract Charges VendorContractCharges	589000
CY2022	amrn	Vendor Contract Charges VendorContractCharges	4216000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	10972000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	13526000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	13717000
CY2023	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	39228000
CY2022	amrn	Cost Of Goods And Services Sold Restructuring Inventory CostOfGoodsAndServicesSoldRestructuringInventory	18078000
CY2023	amrn	Restructuring Charges Stock Forfeitures RestructuringChargesStockForfeitures	1034000
CY2022	amrn	Restructuring Charges Stock Forfeitures RestructuringChargesStockForfeitures	591000
CY2023	amrn	Restructuring Cash Obligations Charges Includes Cost Of Goods Sold Restructuring Inventory And Stock Forfeitures RestructuringCashObligationsChargesIncludesCostOfGoodsSoldRestructuringInventoryAndStockForfeitures	51234000
CY2022	amrn	Restructuring Cash Obligations Charges Includes Cost Of Goods Sold Restructuring Inventory And Stock Forfeitures RestructuringCashObligationsChargesIncludesCostOfGoodsSoldRestructuringInventoryAndStockForfeitures	32195000
CY2021	amrn	Restructuring Cash Obligations Charges Includes Cost Of Goods Sold Restructuring Inventory And Stock Forfeitures RestructuringCashObligationsChargesIncludesCostOfGoodsSoldRestructuringInventoryAndStockForfeitures	13717000
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	192000
CY2023	amrn	Restructuring Cash Obligations Charges Includes Cost Of Goods Sold Restructuring Inventory And Stock Forfeitures RestructuringCashObligationsChargesIncludesCostOfGoodsSoldRestructuringInventoryAndStockForfeitures	51234000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	37837000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	13589000
CY2023	amrn	Capitalized Cost CapitalizedCost	300000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P7Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	33188000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32859000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13884000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11079000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19304000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21780000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2800000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2915000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2915000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2655000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2546000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2546000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5727000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19304000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	155128000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	126391000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5373000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	52297000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	175730000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	213664000
CY2023Q4	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	336231000
CY2022Q4	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	392352000
CY2023	amrn	Inventory Deemed Not Saleable InventoryDeemedNotSaleable	5100000
CY2022	amrn	Finished Goods Deemed Not Saleable FinishedGoodsDeemedNotSaleable	9600000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	77600000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	163600000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1493000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3346000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1379000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2472000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	874000
CY2023	us-gaap	Depreciation Depreciation	200000
CY2022	us-gaap	Depreciation Depreciation	600000
CY2021	us-gaap	Depreciation Depreciation	600000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18942000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20302000
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1009000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1672000
CY2023Q4	amrn	Accrued Liabilities Sales Allowances Current AccruedLiabilitiesSalesAllowancesCurrent	145034000
CY2022Q4	amrn	Accrued Liabilities Sales Allowances Current AccruedLiabilitiesSalesAllowancesCurrent	134869000
CY2023Q4	amrn	Accrued Restructuring Current AccruedRestructuringCurrent	13589000
CY2022Q4	amrn	Accrued Restructuring Current AccruedRestructuringCurrent	192000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25600000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	35643000
CY2023Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	204174000
CY2022Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	192678000
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	37000000
CY2023Q4	amrn	Accured Estimated Liability AccuredEstimatedLiability	8000000
CY2023Q4	amrn	Additional Estimated Liability AdditionalEstimatedLiability	7800000
CY2023Q4	amrn	Accured Estimated Liability AccuredEstimatedLiability	8000000
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1239763
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	33303
CY2023	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	1882001
CY2022	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	59686
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19182000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	18363000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8221000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	128000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	7.54
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1240000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.50
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27956000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	131000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12333000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	14300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	23800000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	27114000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	113000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	22984000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8200000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16600000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	21100000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1900000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2900000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11700000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6800000
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	14800000
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	23000000
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	9800000
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	11400000
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	13900000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	16300000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	15646000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26213000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36938000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8900000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8200000
CY2023	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	700000
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	500000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22040000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24034000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	16000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2261000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	9107000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2248000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2204000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5782000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	238000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18658000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18715000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22040000
CY2021	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	-546000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5442000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1998000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2023Q4	amrn	Deferred Tax Liabilities Subject To Expiration DeferredTaxLiabilitiesSubjectToExpiration	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	15881000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5358000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	10222000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53670000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-103805000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11291000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1597000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	562000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2690000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	243000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	573000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	716000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3602000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	863000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	156000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5442000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1998000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3562000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	9927000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3721000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5222000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-934000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	284000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3057000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-15408000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1646000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1619000
CY2023	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	6415000
CY2022	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	5083000
CY2023Q4	amrn	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	1971000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13418000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25952000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2823000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	8042000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	9141000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-4416000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6415000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5083000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-546000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	31000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2344000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	5249000
CY2023	amrn	Income Tax Reconciliation Windfall Tax Benefit IncomeTaxReconciliationWindfallTaxBenefit	-4500000
CY2022	amrn	Income Tax Reconciliation Windfall Tax Benefit IncomeTaxReconciliationWindfallTaxBenefit	-3569000
CY2021	amrn	Income Tax Reconciliation Windfall Tax Benefit IncomeTaxReconciliationWindfallTaxBenefit	-81000
CY2021	amrn	Income Tax Reconciliation Disqualifying Disposition Windfall IncomeTaxReconciliationDisqualifyingDispositionWindfall	219000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	376000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	958000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1170000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	4187000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	424000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-8372000
CY2023	amrn	Income Tax Rate Reconciliation Foreign Exchange IncomeTaxRateReconciliationForeignExchange	-2921000
CY2022	amrn	Income Tax Rate Reconciliation Foreign Exchange IncomeTaxRateReconciliationForeignExchange	7859000
CY2021	amrn	Income Tax Rate Reconciliation Foreign Exchange IncomeTaxRateReconciliationForeignExchange	4109000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	141000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1542000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	863000
CY2023	amrn	Income Tax Rate Reconciliation Uncertain Tax Positions IncomeTaxRateReconciliationUncertainTaxPositions	780000
CY2022	amrn	Income Tax Rate Reconciliation Uncertain Tax Positions IncomeTaxRateReconciliationUncertainTaxPositions	-3290000
CY2021	amrn	Income Tax Rate Reconciliation Uncertain Tax Positions IncomeTaxRateReconciliationUncertainTaxPositions	5160000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	1939000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	2935000
CY2022	amrn	Income Tax Reconciliation Loss Of Tax Attributes IncomeTaxReconciliationLossOfTaxAttributes	8255000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5442000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1998000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	154086000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	136862000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9929000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11616000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2409000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2639000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4723000
CY2021Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	282226000
CY2022	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	802115000
CY2022Q4	amrn	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	2583000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	7916000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	11895000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	176311000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170318000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	171793000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	165378000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4518000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4940000
CY2023Q4	amrn	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	3050000
CY2022Q4	amrn	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	3337000
CY2023Q4	amrn	Deferred Tax Liability Lease Asset DeferredTaxLiabilityLeaseAsset	1468000
CY2022Q4	amrn	Deferred Tax Liability Lease Asset DeferredTaxLiabilityLeaseAsset	1603000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4518000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4940000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	165378000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160295000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3494000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12942000
CY2023	amrn	Foreign Exchange Valuation Allowances ForeignExchangeValuationAllowances	2921000
CY2022	amrn	Foreign Exchange Valuation Allowances ForeignExchangeValuationAllowances	-7859000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	171793000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	165378000
CY2023Q4	amrn	Deferred Tax Assets Operating Loss Carryforwards Change In Amount DeferredTaxAssetsOperatingLossCarryforwardsChangeInAmount	-125600000
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2023Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2700000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1700000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1900000
CY2023	amrn	Accounts Receivable Credit Period AccountsReceivableCreditPeriod	P45D
CY2022	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	-592000
CY2022	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	628406000
CY2022	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	265006000
CY2022Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	191521000
CY2023	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	835685000
CY2023	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	17378000
CY2023	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	681958000
CY2023	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	156369000
CY2023Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	171501000
CY2023	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15346000
CY2023	amrn	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	8090000
CY2023	amrn	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	18586000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4850000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16709000
CY2022	amrn	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	6000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1369000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15346000
CY2023	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	1892000
CY2022	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	1366000
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	16182000
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	2000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115
CY2023	amrn	Operating Lease Change In Weighted Average Discount Rate Percent OperatingLeaseChangeInWeightedAverageDiscountRatePercent	0.01
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10600000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11600000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8300000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9100000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	3200000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2800000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	1096000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter	218000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	1878000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	828000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	7133000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2967000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2292000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2181000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1964000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1978000
CY2023Q4	amrn	Lessee Operating Lease Liability Payments Due Year Six And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter	3273000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14655000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4048000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1870000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8737000
CY2023	us-gaap	Sales Type Lease Interest Income SalesTypeLeaseInterestIncome	61000
CY2023	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	912000
CY2023	us-gaap	Sales Type Lease Impairment Loss SalesTypeLeaseImpairmentLoss	61000
CY2023	us-gaap	Lease Income LeaseIncome	912000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	117000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1006000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	119000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1029000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	122000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1051000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears	125000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1073000
CY2023Q4	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears	127000

Files In Submission

Name	View Source	Status
0000950170-24-022636-index-headers.html	Edgar Link	pending
0000950170-24-022636-index.html	Edgar Link	pending
0000950170-24-022636.txt	Edgar Link	pending
0000950170-24-022636-xbrl.zip	Edgar Link	pending
amrn-20231231.htm	Edgar Link	pending
amrn-20231231.xsd	Edgar Link	pending
amrn-ex10_43.htm	Edgar Link	pending
amrn-ex21_1.htm	Edgar Link	pending
amrn-ex23_1.htm	Edgar Link	pending
amrn-ex31_1.htm	Edgar Link	pending
amrn-ex31_2.htm	Edgar Link	pending
amrn-ex32_1.htm	Edgar Link	pending
amrn-ex97_1.htm	Edgar Link	pending
amrn-20231231_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
img152338051_0.jpg	Edgar Link	pending
img152338051_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRN
AMARIN CORP PLC\UK Stock $amrn

2023 Q4 Form 10-K Financial Statement

#000095017024022636 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN AMARIN CORP PLC\UK Stock $amrn

2023 Q4 Form 10-K Financial Statement

#000095017024022636 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN
AMARIN CORP PLC\UK Stock $amrn